U.S. Stock Market Movement | Vaccine concept stocks show mixed performance, Novavax Pharmaceuticals rises by over 5.4%
On Friday, vaccine concept stocks showed mixed performance, with Novavax Medicine seeing a rise in stock price, up over 5.4% to $12.57 as of press time. The company announced that its updated COVID-19 vaccine has been launched in the United States for the prevention of COVID-19 in individuals aged 12 and above. Moderna fell by nearly 4% to $66.92. Moderna plans to launch a mRNA-based skin cancer vaccine as early as next year. It is reported that Moderna has released mid-term data on its personalized cancer vaccine named mRNA-4157, which is used in combination with Merck's PD-1 therapy Keytruda for the treatment of melanoma. Pfizer saw a slight decrease of 0.22%
According to the Wise Finance APP, on Friday, vaccine concept stocks showed mixed performance. Novavax (NVAX.US) saw its stock price rise, with an increase of over 5.4% to $12.57 as of the time of publication. The company announced that its updated COVID-19 vaccine has been launched in the United States for the prevention of COVID-19 in individuals aged 12 and above.
Moderna (MRNA.US) fell by nearly 4% to $66.92. Moderna plans to launch a mRNA-based skin cancer vaccine as early as next year. It is reported that Moderna has released mid-term data on its personalized cancer vaccine named mRNA-4157, which is combined with Merck's (MRK.US) PD-1 therapy Keytruda for the treatment of melanoma. Pfizer (PFE.US) saw a slight decrease of 0.22%